[Federal Register Volume 71, Number 188 (Thursday, September 28, 2006)]
[Notices]
[Pages 56991-56993]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-15975]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Mammalian Cell Surface Display of Fvs for Rapid Antibody Maturation
Description of Technology: This technology describes a new method
of cell surface display of single chain antibodies for affinity
maturation in a mammalian system. Cells expressing a rare mutant
antibody with higher affinity were enriched about 240 fold by a single-
pass cell sorting from a large excess of cells expressing wild-type
antibodies with slightly lower affinity. Additionally, a highly
enriched mutant with increased binding affinity for CD22 after a single
selection of a combinatory library randomizing an intrinsic antibody
hotspot was successfully obtained. The system is compatible with other
mammalian expression systems and it is a rapid, simple and robust
procedure. The method can be useful in isolating high affinity
antibodies for cancer, AIDS and other diseases.
Applications: (1) A new method of displaying Fvs on human cells;
(2) A new method useful to isolate new high affinity antibodies for
cancer, AIDS and other diseases.
Market: The method has a potential several billion dollar market as
it can be potentially used in immunotherapeutic approaches for the
treatment of cancer, AIDS and other diseases.
Development Status: The technology is currently in pre-clinical
stage of development.
Inventors: Drs. Ira Pastan and Mitchell Ho (NCI).
Publication: Mo Ho, S Nagata, I Pastan. Isolation of anti-CD22 Fv
with high affinity by Fv display on human cells. Proc Natl Acad Sci
USA. Jun 20;103(25):9637-9642. Epub 2006 Jun 8, doi 10.1073/
pnas.0603653103.
Patent Status: U.S. Provisional Application No. 60/794,212 filed 21
Apr 2006 (HHS Reference No. E-200-2006/0-US-01)
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Jesse S. Kindra, J.D.; 301/435-5559;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute
Laboratory of Molecular Biology is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize Mammalian Cell Surface Display of
Fvs
[[Page 56992]]
for Rapid Antibody Maturation. Please contact Betty Tong, PhD at 301-
496-0477 or [email protected] for more information.
Methods of Identifying and Treating Tumors that Express Erythropoietin
Receptor Protein (EPO R)
Description of Invention: The inventors have discovered that EPO
and EPOR are co-expressed in tumors of von Hippel-Lindau (VHL) patients
and in tumors of sporadic renal tumor patients. Ligands that bind to
EPOR but do not activate the receptor can target specific tumor cells
with minimal detrimental effect on normal cells.
Applications: (1) Treatment and diagnosis of renal tumors in
sporadic and kidney dialysis patients; (2) Treatment and diagnosis of
multiple tumors in different organs in patients with von Hippel-Landau
patients; (3) Treatment and diagnosis of pheochromocytomas; (4)
Treatment and diagnosis of eye and CNS hemangioblastomas.
Inventors: Zhengping Zhuang et al. (NINDS).
Patent Status: International Patent Application No. PCT/US2005/
033850 filed 20 Sep 2005, which published as WO 2006/034354 on 30 Mar
2006 (HHS Reference No. E-274-2004/0-US-02).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Thomas P. Clouse, J.D.; 301/435-4076;
[email protected].
Collaborative Research Opportunity: In addition to licensing, the
technology is available for further development through collaborative
research opportunities with the inventors. For further information
regarding collaborative research opportunities, please contact Dr.
Martha Lubet at e-mail: [email protected] or telephone: 301/435-3120.
Diagnostic and Therapeutic Use of SPANX-N Genes in Cancer and Fertility
Description of Technology: Cancer is the second leading cause of
death in United States and it is estimated that there will be
approximately 600,000 deaths caused by cancer in 2006. In spite of the
success of cancer screening and early diagnosis cancer still remains a
life threatening disease. There is a great need for the development of
new markers and new therapeutic strategies that would more accurately
predict the outcome of the disease and aid in the proper management of
cancer. Antibody-based strategies have taken a lead among the new
cancer therapeutic approaches.
This technology describes the identification of the link between
expression of individual members of the SPANX-gene cluster and
malignancies including prostate cancer. SPANX-genes consist of two
subfamilies, SPANX-A/D and SPANX-N1/N5. The invention provides SPANX
polypeptides, nucleic acids and antibodies that could be useful for
detecting and treating prostate or other cancers. The SPANX-N genes are
a family of related genes that are expressed in normal testis and in
tumor cells in humans including melanoma, bladder carcinomas and
myelomas. The SPANX cancer/testis antigens thus represent good
candidates for diagnosis or treatment of several cancers. The present
invention also describes a new approach for mutation screen of the
SPANX gene cluster, including gene amplification, linking
predisposition to prostate cancer with a specific architecture of the
SPANX gene cluster. Additionally, due to the differential localization
of SPANX-proteins in the spermatozoa, the mutational screen can be also
used for diagnostics of infertility. Developed antibodies against
SPANX-A/D and SPANX-N1/N5 proteins can be used for (i) diagnostics of
cancer, (ii) diagnostics of infertility and iii) for the development of
new contraceptives.
Applications: (1) Novel antibodies to SPANX-A/D and SPANX-N1/N5;
(2) New approach for mutation screen of SPANX gene cluster; (3)
Antibodies can be used for diagnosis and development of
immunotherapeutics for several cancers including prostate; (4)
Compounds can also be used for the diagnosis of infertility and
development of new contraceptives.
Market: (1) 600,000 deaths from cancer related diseases estimated
in 2006; (2) The technology platform involving novel antibodies for the
diagnosis and therapeutics of several cancers has a potential market of
more than 7 billion U.S. dollars; (3) The technology platform has
additional market in fertility related diagnostics and therapeutics.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Natalay Kouprina (NCI) et al.
Publications:
1. N Kouprina et al. The SPANX gene family of cancer/testis-
specific antigens: rapid evolution and amplification in African great
apes and hominids. Proc Natl Acad Sci USA. 2004 Mar 2;101(9):3077-3082.
Epub 2004 Feb 18, doi 10.1073/pnas.0308532100.
2. N Kouprina et al. Dynamic structure of the SPANX gene cluster
mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome
Res. 2005 Nov;15(11):1477-1486.
3. N Kouprina and V Larionov. TAR cloning: Insights into gene
function, long-range haplotypes, and genome structure and evolution.
Nature Reviews Genetics, 7: In press, 2006.
4. N Kouprina et al. SPANX-N gene cluster at Xq27: A new group of
cancer-testis antigen genes encoding acrosomal proteins. Submitted to
Cancer Research, 2006.
Patent Status: U.S. Provisional Application No. 60/636,811 filed 15
Dec 2004 (HHS Reference No. E-212-2004/0-US-01); PCT Application No.
PCT/US2005/045317 filed 15 Dec 2005, which published a WO 2006/065938
on 22 Jun 2006 (HHS Reference No. E-212-2004/1-PCT-01)
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Mojdeh Bahar, J.D.; 301/435-2950;
[email protected].
Collaborative Research Opportunity: The National Cancer Institute
Laboratory of Biosystems and Cancer is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize this new diagnostic marker
for malignancy and infertility and new targets for immuno-cancer
therapy. Please contact Betty Tong, Ph.D. at 301-594-4263 or
[email protected] for more information.
Cancer Peptides of NY-ESO-1/CAG-3
Description of Technology: The current invention embodies the
identification, isolation and cloning of a gene encoding a novel tumor
antigen, NY ESO-1/CAG-3, as well as cancer peptides thereof and
antigenic cancer epitopes contained within the cancer peptides. This
novel antigen is recognized by cytotoxic T lymphocyte clones derived
from the TIL586 (tumor infiltrating lymphocyte) cell line in an HLA
restricted manner.
The inventors believe that cancer peptides which are encoded by the
NY ESO-1/CAG-3 gene represent potential cancer vaccines, protecting an
individual from development of cancer by inhibiting the growth of cells
or tumors which express the NY ESO-1/CAG-3 antigen. Also embodied in
the invention are pharmaceutical compositions comprising the NY ESO-1/
CAG-3 antigen, peptide, or an antigenic cancer epitope thereof in
combination with one or more immunostimulatory molecules. These
compositions represent potential anticancer therapeutics, stimulating
NY
[[Page 56993]]
ESO-1/CAG-3-specific T cells to elicit an anti-cancer immunogenic
response and thereby eliminating or reducing the cancer. While these
vaccines and pharmaceutical compositions may be developed for use
against a variety of cancers, data obtained to date indicate that they
may be of particular value for use against melanoma.
Methods for diagnosing cancer via the detection of NY ESO-1/CAG-3
are also embodied in the invention.
Inventors: Steven A. Rosenberg (NCI) et al.
Patent Status: U.S. Patent No. 7,084,239 issued 01 Aug 2006 (HHS
Reference No. E-265-1997/0-US-04).
Licensing Status: Available for non-exclusive licensing or
exclusive licensing.
Licensing Contact: Jesse S. Kindra, J.D.; 301/435-5559;
[email protected].
Dated: September 20, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-15975 Filed 9-27-06; 8:45 am]
BILLING CODE 4140-01-P